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Abstract
Candida albicans is the major fungal pathogen of humans. Fungal adhesion to host cells is the first step of mucosal
infiltration. Antimicrobial peptides play important roles in the initial mucosal defense against C. albicans infection. LL-37 is
the only member of the human cathelicidin family of antimicrobial peptides and is commonly expressed in various tissues
and cells, including epithelial cells of both the oral cavity and urogenital tract. We found that, at sufficiently low
concentrations that do not kill the fungus, LL-37 was still able to reduce C. albicans infectivity by inhibiting C. albicans
adhesion to plastic surfaces, oral epidermoid OECM-1 cells, and urinary bladders of female BALB/c mice. Moreover, LL-37-
treated C. albicans floating cells that did not adhere to the underlying substratum aggregated as a consequence of LL-37
bound to the cell surfaces. According to the results of a competition assay, the inhibitory effects of LL-37 on cell adhesion
and aggregation were mediated by its preferential binding to mannan, the main component of the C. albicans cell wall, and
partially by its ability to bind chitin or glucan, which underlie the mannan layer. Therefore, targeting of cell-wall
carbohydrates by LL-37 provides a new strategy to prevent C. albicans infection, and LL-37 is a useful, new tool to screen for
other C. albicans components involved in adhesion.
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Introduction
Candida albicans is the major fungal pathogen that affects
humans. Although C. albicans is a commensal organism on the
cutaneous and mucosal surfaces of oral, gastrointestinal, urinary,
and vaginal tracts of healthy individuals [1,2], it is also an
opportunistic pathogen and can cause infections ranging from
superficial mucosal infections to hematogenously disseminated
candidiasis. In immunocompromised patients, C. albicans is
responsible for a number of life-threatening infections [1,2].
Moreover, with the rapidly expanding use of medical devices (e.g.,
indwelling catheters) and increases in the number of patients
receiving antibiotic and immunosuppressive therapies, there is an
increased risk of fungal penetration through mucosal barriers with
subsequent entry into the blood stream, which often leads to multi-
organ infections. Consequently, C. albicans is the leading cause of
nosocomial bloodstream infections and has a mortality rate of 40%
[3,4].
C. albicans pathogenesis studies have suggested that several steps
may lead to mucosal infection, i.e., early colonization, invasion,
and late tissue disruption [5,6]. C. albicans first colonizes and
proliferates on the mucosal surfaces of host epithelial cells; these
events are followed by invasion and tissue damage [7,8].
Therefore, C. albicans adhesion is the first step in infection and
allows the pathogen to persist on mucosal surfaces. As the
outermost layer of C. albicans, the cell wall interacts with the host
cells [9]. The cell wall of C. albicans contains many different
carbohydrates and proteins that come into contact with epithelial
cells and facilitate cell-cell interconnections [10,11].
Host cells defend against Candida infection by producing
cytokines [12], chemokines [13], and antimicrobial peptides
(AMPs) [14,15]. Human AMPs are the first line of mucosal
immunity [16,17]. AMPs are generally short (10 to 50 amino acid
residues), positively charged (generally +2t o+9), and contain
$30% hydrophobic residues [18]. Consequently, when folded,
many of these peptides exhibit amphiphilic, helical structures and
can form pores in microbial membranes, which causes membrane
rupture and eventual cell death [19]. Recent studies have
indicated that AMPs can also inhibit the biosynthesis of microbial
cell walls, nucleic acids, and proteins, and can inhibit the activity
of certain microbial enzymes [19,20,21,22]. In humans, different
types of AMPs are synthesized and secreted by various cells and
tissues, including skin, mucosal surfaces, neutrophils, and epithelia
[23].
LL-37 is the only member of the human cathelicidin family of
AMPs [24]. LL-37 is stored in specific neutrophil granules as an
inactive propeptide, which is cleaved extracellularly to yield the
mature, active peptide [25]. In addition to exhibiting broad-
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has other activities related to host defense, including chemotactic
migration, endotoxin neutralization, angiogenesis, and wound
healing [26,27]. To date, studies concerning the effects of LL-37
on C. albicans have been few in number. In a study of the
candidacidal activity of AMPs, LL-37 was found to remain
associated with the C. albicans cell surface, whereas other AMPs
(e.g., histatin 5) translocated through the membrane and
accumulated intracellularly [28].
For the study reported herein, we further investigated the effects
of LL-37 on C. albicans. We show that LL-37 significantly reduced
C. albicans attachment to an abiotic surface, to oral epidermis, and
to murine urinary bladders. In addition, LL-37 was found to
associate with C. albicans cell-wall carbohydrates, which caused the
cells to aggregate and consequently may help protect host cells
against infection. To our knowledge this is the first report showing
that LL-37 can interfere with the adhesion of a fungal pathogen to
human cells. These results suggest the potential for new
therapeutic agents that can target the cell-wall carbohydrates of
C. albicans and the use of AMPs to prevent C. albicans colonization
and infection. Moreover, LL-37 might be used to screen for other
adhesion molecules on the cell surface of C. albicans and/or other
fungal pathogens.
Results
LL-37 kills C. albicans
The ability of LL-37 to kill C. albicans was measured by a spot
assay and a FUN-1 assay that incorporated flow cytometry (21).
For the spot assay, cell viability after LL-37 treatment was visually
compared with that of control cells (no LL-37 treatment). We
found that cell viability was more sensitive to higher concentra-
tions of LL-37 (20 to 40 mg/ml) as opposed to lower concentra-
tions (5 and 10 mg/ml) or no treatment (Fig. 1A). To quantitatively
measure cell mortality, FUN-1 staining was used to distinguish
between dead and living cells. Concentrations of LL-37 $20 mg/
ml induced cell death. At 40 mg/ml LL-37, ,60% of the cells were
killed (Fig. 1B). Therefore, LL-37 had a candidacidal effect on C.
albicans at doses $20 mg/ml.
LL-37 affects adhesion of C. albicans to polystyrene
We found that after treatment with 5 mg/ml LL-37, cells were
more easily centrifuged and did not adhere to centrifuge tubes to
the extent that control cells did (Supplement Fig. S1). Cell
adhesion is the first step during C. albicans colonization of host
tissues and is required for infection. Adhesion is conferred by the
binding of C. albicans adhesins to amino acid or sugar residues on
the host cell surface [29]. Adhesins may also promote cell binding
to abiotic substrates, e.g., plastic prostheses and catheters [29]. We
therefore suspected that LL-37 might affect interactions between
the C. albicans cells and the substratum upon which they can
proliferate. To test this hypothesis, C. albicans were treated with
sub-lethal doses of LL-37 (0.1–10 mg/ml), and the extent of C.
albicans attachment to polystyrene dishes was measured using
the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide (XTT) reduction assay and the whole-cell enzyme-
linked immunosorbent assay (ELISA). The extent of attachment
decreased with increasing LL-37 concentration (Fig. 2A). Floating
cells were collected and spotted onto YPD agar to assess cell
viability. The number of colonies derived from these cells
depended on the LL-37 concentration and increased between
0.1 and 10 mg/ml LL-37 (Fig. 2B), suggesting that the LL-37
concentrations used in the adhesion assays were not substantially
candidacidal. Together, the results shown in Fig. 1 and 2A
suggested that low doses of LL-37 inhibited the adhesion of C.
albicans to polystyrene, that this effect was not directly related to
the ability of LL-37 to kill the cells (Fig. 2B), and that mechanisms
not involved in the candidacidal effect might be responsible for
adhesion loss. We hypothesized that one such mechanism might
involve a direct interaction between LL-37 and fungal cells, which
was supported by the finding that the fungal cells aggregated after
treatment with LL-37 (Fig. 2C). Morphological structures, e.g., the
germ tube or hyphae, tend to cause aggregation of C. albicans cells.
However, as seen in Fig. 2C, most aggregated cells were in the
form of yeast. Therefore, LL-37, but not cell morphology, caused
the cells to aggregate.
LL-37 induces cell aggregation and reduces cell
attachment to polystyrene by directly binding to C.
albicans
To determine if LL-37 caused the cells to aggregate, which in
turn caused them to detach from the plastic dishes, floating cells
were collected after LL-37 treatment and characterized by optical
microscopy. The extent of floating cell aggregation was directly
proportional to LL-37 concentration (Fig. 3A).
Given the dose-dependent effect of LL-37 on cell aggregation,
we hypothesized that LL-37 may directly bind to the C. albicans cell
surface, thereby interfering with cell adhesion to polystyrene. To
Figure 1. Candidacidal activity of LL-37. (A) Candidacidal activity
of LL-37 was determined using a spot assay. The C. albicans SC5314
strain was treated with different concentrations of LL-37, and then cells
that had been ten-fold serially diluted were spotted onto YPD agar. All
experiments were performed in triplicate. (B) The candidacidal activity
of LL-37 was monitored by FUN-1 staining. LL-37-treated cells were
stained with FUN-1 for 30 min at 30uC. The number of cells killed by LL-
37 was normalized with respect to the number of control cells (no LL-37
treatment) and reported as a percentage. Data are presented as the
average of three independent experiments, and the statistical
significance of the experimental data in comparison to the control
data was determined using Student’s t-test (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0017755.g001
LL-37 Inhibits C. albicans Adhesion
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17755test this possibility, LL-37-binding assays were performed. C.
albicans cells were treated with BA-LL37, and floating cells were
collected. BA-LL37 bound to these cells as assessed by western
blotting that used horseradish peroxidase–conjugated streptavidin
(SA-HRP) for detection. Direct binding of LL-37 to the floating
cells was obvious when the LL-37 concentrations were 10 and
20 mg/ml (Fig. 3B). However, smaller numbers of floating cells
might have been the cause of the non-detectable LL-37 binding at
the smaller doses. To test this possibility, we also assessed LL-37
binding using flow cytometry in conjunction with SA-4,6-
dichlorotriazinyl aminofluorescein (SA-DTAF) detection. For this
system, the binding of BA-LL37 to C. albicans cells was observed at
a dose of 1 mg/ml (Fig. 3C). These results strongly indicated that
LL-37 directly bound to C. albicans and induced cell aggregation,
which consequently removed the cells from the polystyrene.
To investigate if the inhibition of adhesion was LL-37 specific,
two other types of AMPs, human b-defensin 3 (hBD-3) and
histatin 5 (Hst 5), were tested using the adhesion assay. Hst 5 has a
linear, non-helical structure, hBD-3 folds into a b-sheet, and the
LL-37 conformation is helical [30]. All three AMPs have
candidacidal activity [30]. Equivalent molar concentrations of
these AMPs were used in all assays. After C. albicans cells were
incubated with 2.12 mM BA-hBD3, BA-Hst 5, or BA-LL37
(2.12 mM BA-LL37 is ,10 mg/ml LL-37), XTT reduction assays
and whole-cell ELISAs were performed. In comparison with the
level of control-cell adhesion to polystyrene, BA-Hst 5 and BA-
hBD3 reduced the adhesion level of C. albicans cells by ,10–30%,
whereas BA-LL37 reduced adhesion by 60–80% (Fig. 4A). AMP-
induced aggregation of floating cells was then examined by
microscopy, and the number of aggregates was recorded. The
extent of cell aggregation was greatest for BA-LL37-treated cells,
and large aggregates were observed. Conversely, the BA-hBD3-
treated cells formed few aggregates, and those treated with BA-Hst
5 did not aggregate (Fig. 4B). Flow cytometry was also used to
assess if the AMPs bound to the cells. According to the
fluorescence intensities, cells bound by BA-hBD3 and BA-Hst 5
were only 10–15% of that found for BA-LL37-treated cells
(Fig. 4C). To exclude the possibility that the inhibitory effects of
the AMPs on cell adhesion were caused by cell death, cells were
incubated with the same molar concentrations of the AMPs as
used for the adhesion assay, and then cell viability was assessed
using the spot assay. Cell death was not observed when cells were
treated with BA-LL37 or BA-Hst 5, although almost half of the cell
population was killed after BA-hBD3 treatment (Fig. 4D). In
Figure 2. Inhibition of C. albicans adhesion by LL-37. (A) Cell adhesion to an abiotic surface (polystyrene). C. albicans cells were incubated in
RPMI-1640 in polystyrene wells for 30 min and then washed three times with PBS to remove unattached cells. The attached cells were detected by
measuring the reduction of XTT and by whole-cell ELISA using an antibody against C. albicans. All experiments were done in triplicate, and each was
repeated three (XTT reduction assay) or four times (cell ELISA). The statistical significance for the number of treated vs. control cells was determined
using Student’s t-test (*, p,0.05; **, p,0.01; ***, p,0.001). (B) Spot assay to determine the number of viable, floating cells after LL-37 treatment.
Different concentrations of LL-37 were incubated with cells in RPMI-1640 for 30 min; then the floating cells were collected, diluted onto YPD agar,
and incubated at 30uC overnight. All experiments were done in triplicate, and each was repeated twice. (C) The morphology of the floating cells after
LL-37 treatment was visualized by microscopy (4006magnification).
doi:10.1371/journal.pone.0017755.g002
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and peptide-cell association assays (Fig. 4), these results indicated
that, of the three AMPs tested, only LL-37 inhibited C. albicans
adhesion to polystyrene by directly binding to cell surface and
causing cell aggregation.
LL-37 binds to C. albicans cell-wall polysaccharides and
thereby reduces C. albicans adhesion
The cell wall is the outmost layer of C. albicans and, as such,
interacts with the environment and host cells [31]. The content of
the C. albicans cell wall is ,80–90% carbohydrate and contains
different carbohydrates [2]. LL-37 contains an XBBXBX motif
(where X is a hydrophobic or uncharged residue, and B is a basic
residue) that is responsible for the binding of LL-37 to
glycosaminoglycans, e.g., heparin and dermatan sulfate [32].
To evaluate the role of carbohydrates in LL37-mediated
inhibition of C. albicans adhesion, cell-wall carbohydrates were
removed. Concanavalin A (Con A) specifically binds a-D-
mannose and a-D-glucose, and BA-Con A was used to monitor
the extent of deglycosylation. After deglycosylation, the amount
of BA-Con A that bound C. albicans cells decreased by ,50%,
which represents the removal of ,50% of the cell-wall
carbohydrates. After removal of the carbohydrates, the binding
of BA-LL37 to the C. albicans cells was reduced by ,30%
compared with its binding to non-deglycosylated cells (Fig. 5A).
Moreover, pull-down assays verified the LL-37/polysaccharide
interaction. Since glucan and chitin in solutions will be insoluble,
these two polysaccharides and mannan-agarose were used to
associate with LL-37 and to pull LL-37 down. Mannan-agarose,
glucan, and chitin were each incubated with BA-LL37, after
which unbound peptide was separated from the carbohydrates by
centrifugation. LL-37 bound directly to these polysaccharides
(Fig. 5B). The interaction of each polysaccharide with LL-37 was
dose dependent.
To identify the types of carbohydrates targeted by LL-37
binding, the three monosaccharide compositions of the C. albicans
cell wall, D-glucose, N-acetyl-D-glucosamine, and mannose [33],
were each included in a cell-adhesion assay. Monosaccharides
were pre-incubated with LL-37 to form monosaccharide/LL-37
complex, the inhibition effect of LL-37 on adhesion was thereby
suppressed. As shown in Fig. 5C, D-glucose significantly rescued
LL37-mediated adhesion inhibition while N-acetyl-D-glucosamine
and D-mannose also possessed some potential to neutralize the
effect of LL-37. We thus concluded that LL-37 might bind to
monosaccharides to prevent cell adhesion of C. albicans (Fig. 5C).
However, polysaccharides, not monosaccharides, account for
.90% of the C. albicans cell-wall carbohydrates [34], and
monosaccharides can not properly reflect structure and function
of the cell wall. Therefore, polysaccharides were also tested in
adhesion assays (Fig. 5D). In the absence of LL-37, chitin and
Saccharomyces cerevisiae mannan had no significant effect on cell
adhesion, whereas S. cerevisiae glucan slightly decreased and C.
albicans mannan largely increased the level of adhesion the level of
adhesion (Fig. 5D). This data was consistent with the finding that
C. albicans mannan enhances C. albicans adhesion to plastic [35].
Moreover, no significant difference was shown by comparing cells
Figure 3. LL-37-induced C. albicans cell aggregation and LL-37 binding to C. albicans. (A) Visualization by microscopy of C. albicans cell
aggregation after LL-37 treatment. C. albicans cells were incubated with LL-37 in RPMI-1640, and the floating cells were then injected into m-Slides
and visualized by microscopy (2506magnification). Cell aggregates are indicated by the arrowheads. (B) Western blot showing that LL-37 bound to
floating C. albicans cells. C. albicans were incubated with BA-LL37 in RPMI-1640, and the contents of the floating cells were subjected to Tricine SDS-
PAGE, blotted, and detected with SA-HRP. BA-LL37 (10 mg) served as the positive control. (C) Flow cytometry showing that LL-37 bound to C. albicans
cells. Various concentrations of BA-LL37 were incubated with C. albicans in PBS at 4uC overnight, and then the levels of cell-bound BA-LL37 were
assessed by flow cytometry that used SA-DTAF for detection. The data shown are representative of two additional independent experiments. FL1-H
means the extent of fluorescence intensity.
doi:10.1371/journal.pone.0017755.g003
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mediated adhesion inhibition of C. albicans was abolished in the
presence of each polysaccharide. If we considered the effect
caused only by LL-37 but not polysaccharedes (i.e. comparing
only between the black columns of Fig. 5D), C. albicans mannan
exhibited the highest extent to relieve LL37-mediated adhesion
inhibition, followed by chitin (Fig. 5D). S. cerevisiae mannan
slightly relieved the adhesion inhibition caused by LL-37
(Fig. 5D). Importantly, the aggregation of floating cells induced
by LL-37 was largely reduced by C. albicans mannan (Fig. 5E).
The aggregations were moderately reduced by chitin but S.
cerevisiae mannan and glucan had only a minor effect on the
floating cell aggregation (Fig. 5E). The dissociation constant (Kd)
values for the C. albicans and S. cerevisiae mannan/LL-37 complexes
were further determined using an Affinity Detection system. The
Kd values were the average of at least two independent
experiments. The Kd for the LL-37/C. albicans mannan complex
was 0.460.1 mM, and that for the LL-37/S. cerevisiae mannan
complex was 4.960.4 mM; this 12-fold decrease in binding
strength indicated that LL-37 preferentially binds C. albicans
mannan. Together, these results demonstrated that LL-37 binds
the polysaccharides of the C. albicans cell wall, especially
mannans, thereby promoting cell aggregation and reducing cell
adhesion.
Figure 4. The inhibition of cell adhesion caused by LL-37 is the result of peptide-cell binding and cell-cell aggregation. (A) Effects of
BA-LL37, BA-Hst 5, and BA-hBD3 on C. albicans adhesion to polystyrene. The molarity of each peptide was 2.12 mM( ,10 mg/ml of BA-LL37). Cells
treated with only biotin served as the negative control. This control was performed for only the XTT assay. Each experiment was performed three
times in triplicate. The Student’s t-test was used to determine the statistical significance of the results (1, p,0.05 and 11, p,0.01 for BA-LL37-treated
vs. control cells; *, p,0.05; **, p,0.01; and ***, p,0.001 for BA-LL37-treated cells vs. BA-Hst 5- or BA-hBD3-treated cells as indicated in the figure). (B)
Microscopy of C. albicans cell aggregation after LL-37 treatment. C. albicans cells were incubated in RPMI-1640 with biotinylated AMPs, and the
floating cells were collected. Arrowheads indicate BA-LL37-treated cell aggregates. (2506magnification.) (C) Flow cytometry to determine the extent
of binding of different AMPs to C. albicans. BA-LL37, BA-Hst 5, or BA-hBD3 (10 mg each) were independently added to C. albicans samples. The
peptide/cell complex was reacted in PBS at 4uC overnight. The Student’s t-test was used to determine the statistical significance of the results
(*, p,0.05 BA-LL37-treated cells vs. BA-Hst 5- or BA-hBD3-treated cells). Each result is the mean 6 SD of two independent assays. (D) Spot assay to
determine the candidacidal activities of the AMPs. BA-LL37, BA-Hst 5, and BA-hBD3 (2.12 mM) were each incubated with C. albicans for 30 min in
RPMI-1640; then mixtures were diluted, spotted onto YPD agar, and incubated overnight. Each experiment was performed three times.
doi:10.1371/journal.pone.0017755.g004
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cells and the urinary bladders of mice
To assess the in vivo effects of LL-37 on C. albicans adhesion, we
examined the ability of C. albicans to adhere to oral epidermal cells
and to a murine urinary tract model [36]. C. albicans is involved in
human oral infections [37], and LL-37 has been shown to diminish
the effects of microbial infections in the oral cavity [14]. To
determine the extent to which C. albicans can adhere to oral
epidermal OECM-1 cells, a cell ELISA was performed. After
30 min pre-incubation with LL-37, the cells were added to the
OECM-1 cells and incubated for half an hour. The adhesion of
the LL37-treated cells was significantly reduced compared with
control cells (Fig. 6A). For C. albicans treated with 20 mg/ml LL-37,
cell adhesion was reduced by .70% (Fig. 6A).
Candida species are often isolated from the urine of patients
suffering from microbial infection in the bladder or urinary tract
[38]. To determine the effects of LL-37 on C. albicans adhesion
within the urinary tract, we used a mouse model. LL-37 (5 mg/ml)
and C. albicans were mixed and then injected into the urinary tract.
An hour after injection, the number of C. albicans cells that had
adhered to the bladders was quantified as colony-forming units
present on agar. The number of C. albicans cells isolated from the
bladders when LL-37 was present was significantly less than that of
the control (Fig. 6B; p=0.0011). Therefore, LL-37 inhibited C.
albicans adhesion both in vitro and in vivo.
Discussion
Human LL-37 is a multifunctional AMP commonly found at
mucosal surfaces at a concentration of ,2–5 mg/ml [39,40].
However, its local concentration can be 30–1,500 mg/ml in
infected or inflamed tissue [41,42]. Recently, the effects of LL-37
on bacterial infections have been the focus of much research. In
the presence of pathogens, human lung epithelia respond by
rapidly increasing LL-37 secretion onto airway surfaces, which
subsequently kills nearby microbes [16]. Bacterial contact with
urinary tract epithelial cells causes rapid production and secretion
of human LL-37 into the urine [36]. Although epithelium-derived
LL-37 substantially protects the urinary tract against infection
Figure 5. Binding of LL-37 to Candida cell-wall polysaccharides reduces Candida adhesion to polystyrene. (A) Flow cytometry to
determine the relative amount of LL-37 bound to deglycosylated C. albicans cells. Cells were mixed with BA-LL37 or BA-Con A, and the binding was
measured by SA-DTAF detection. Each result is the mean 6 SD of two independent assays. (B) BA-LL37 (10 mg) was incubated with mannan-agarose
beads, chitin, or glucan. After washing, the samples were subjected to Tricine SDS-PAGE and detected by western blotting with SA-HRP. BA-LL37
served as the positive control. (C) Monosaccharides reverse the LL-37-mediated inhibition of C. albicans cell adhesion. LL-37 (5 mg/ml) was added to C.
albicans in the absence or presence of 400 mM mannose, D-glucose, and N-acetyl-D-glucosamine (NAC), and XTT reduction assays were performed.
Each experiment was preformed three times in triplicate. The Student’s t-test was used to determine the statistical significance of the results
(*, p,0.05 for LL-37-treated cells in the absence or presence of D-glucose and for LL-37-treated cells vs. control cells). (D) C. albicans cell-wall
polysaccharides reverse LL-37-mediated inhibition of adhesion. LL-37 (5 mg/ml) was added to C. albicans in the absence or presence of 1 mg/ml of a
polysaccharide, and then XTT reduction assays were performed. Each experiment was performed three times in triplicate. The Student’s t-test was
used to determine the statistical significance of the results (11, p,0.01 for LL-37-treated cells vs. control cells; #, p,0.05 for cells incubated with S. c.
(S. cerevisiae) glucan vs. control cells; **, p,0.01 for LL-37-treated cells in the presence of C. a. (C. albicans) mannan or chitin vs. cells treated only with
LL-37). (E) The effects of polysaccharides on the release of LL-37-induced C. albicans cell aggregation. Cells were treated as described above. The
floating cells were collected and examined under a microscope (2506magnification). Arrowheads indicate aggregates.
doi:10.1371/journal.pone.0017755.g005
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been thoroughly characterized.
For the study reported herein, in addition to its known ability to
kill C. albicans, we demonstrated that human LL-37 can prevent C.
albicans adhesion to abiotic and biotic substrates. Similarly, LL-37
has been shown to prevent Escherichia coli from adhering to the
urinary tract of mouse [36] and to inhibit the attachment and
biofilm formation of Pseudomonas aeruginosa and Staphylococcus
epidermidis [41,43] on polystyrene. To our knowledge, however,
our report is the first to show that LL-37 blocks the adhesion of a
fungal pathogen to substrates. We found that physiological
concentrations of LL-37 prevented the adhesion of C. albicans to
abiotic surfaces in vitro and epithelial surfaces in vivo. The effects
appeared to be specific to LL-37 because Hst 5 and hBD-3, two
other candidacidal AMPs, did not inhibit cell adhesion or bind to
C. albicans to the same degree (Fig. 4A and 4C). LL-37, hBD-3, and
Hst 5 have 6, 11, and 12 positive charges, respectively, at
physiological pH [30]. In addition, recombinant LL-37 has a
propensity to aggregate during purification [44]. Therefore, it is
feasible that aggregation of the floating cells was initiated by the
direct binding of LL-37 to the cell surfaces and allowed for
interaction between LL-37 molecules on adjacent cells (Fig. 4B).
At the same molar dose, BA-hBD3 much effectively killed C.
albicans than BA-LL37 and BA-Hst 5 did (Fig. 4D). Together, these
data suggest that the ability of LL-37 to inhibit C. albicans adhesion
was unrelated to its positive charge or killing activity, but instead
was caused by its interaction with the C. albicans cell surface, which
resulted in cell aggregation and their subsequent inability to bind
supporting substrata.
To identify the components of the C. albicans cell wall that
interact with LL-37, we found that mannan, chitin or glucan and
LL-37 associate. The importance of these associations in microbial
infection has been reported. Foschiatti and colleagues showed that
bacteria use exopolysaccharides to bind and segregate AMPs,
thereby reducing the efficiency of the primary innate host defense
[45]. Bergsson and colleagues showed that LL-37 binds to
glycosaminoglycans from lungs afflicted with cystic fibrosis, which
inhibits the ability of LL-37 to kill Pseudomonas [46]. In our study,
LL-37 association with C. albicans cell-wall carbohydrates, in
particular mannans, decreased cell adhesion to substrata both in
vivo and in vitro. This ability is crucial for C. albicans biofilm
formation on an abiotic surface and for colonization on host tissue
during infection [10]. Interestingly, LL-37 bound to chitin, glucan,
and S. cerevisiae mannan, but only C. albicans mannan completely
rescued LL37-mediated cell aggregation and inhibition of cell
adhesion (Fig. 5B, 5D, and 5E). The major difference between the
two mannans is that C. albicans mannan contains b-1,2 linkages
whereas S. cerevisiae mannan does not [47]. b-1,2-linked mannans
act as the adhesins for C. albicans/buccal epithelium complex
formation [35], and when the complex was recognized by galectin-
3, C. albicans death occurred [48]. In an ex vivo assay, a monoclonal
antibody that recognized b-1,2-mannans inhibited C. albicans
attachment to murine splenic marginal-zone macrophages [49].
Dromer and colleagues demonstrated that synthetic b-1,2-
oligomannosides analogs prevented intestinal colonization by C.
albicans [50]. Our results indicated that the reduced cell adhesion
caused by LL-37 was specifically inhibited by C. albicans mannan,
suggesting that the association between LL-37 and that particular
mannan may involve the latter’s b-1,2-linkages. This hypothesis
requires further study. Because higher eukaryotic cells do not have
a cell wall and because LL-37 exerts its effects by binding to cell-
wall components, these components may be drug candidates for
Candida infection.
Although the polysaccharides tested in our study all interacted
with LL-37 (Fig. 5B), when the cells were deglycosylated, BA-LL37
reduced its binding to cell by only ,30% even though ,50% of
the carbohydrates had been removed (Fig. 5A). Therefore, we
cannot exclude the possibility that LL-37 may also interact with
other cell-wall components, e.g., proteins. Proteins represent ,20–
30% of the fungal cell-wall mass [11]. Specifically, mannan is
covalently bound to proteins (mannoproteins), and this form of
mannan accounts for ,40% of the total cell-wall polysaccharides
on the C. albicans exterior [51]. Mannoproteins are involved in cell-
cell recognition and trigger immune responses [52]. Several studies
have showed that AMPs function via their interactions with
microbial proteins. The protein, F. magna adhesion factor, of the
anaerobic bacterium Finegoldia magna, blocks the cytocidal activity
of LL-37 and promotes F. magna colonization and survival in
humans [53]. hBD-3 binds to immobilized recombinant hemag-
glutinin B, a non-fimbrial adhesin from Porphyromonas gingivalis
Figure 6. LL-37 inhibits C. albicans attachment to oral epidermal
cells and mouse bladder mucosa. (A) C. albicans cells were
incubated in RPMI-1640 at 4uC for 30 min with LL-37, after which the
cells were incubated with OECM-1 oral epidermal cells for 30 min. The
extent of binding by C. albicans was determined by cell ELISA. Each
result is expressed as a percentage of that found for untreated cells and
is reported as the mean 6 SD of four experiments. Each experiment was
performed in quadruplicate (*, p,0.05; **, p,0.01 for LL-37-treated
cells vs. control cells). (B) Attachment of C. albicans cells to mouse
urinary bladders. The number of adhered cells for each bladder was
normalized to the average number of cells for all bladders and is
reported as a percentage. Three independent experiments were
performed with six to eight mice per group. Each horizontal line
denotes the median. The difference between 5 mg/ml LL-37-treated
cells and controls was significant (p=0.0011; Student’s t-test).
doi:10.1371/journal.pone.0017755.g006
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tissues [55]. The C. albicans proteins possibly targeted by LL-37
and the significance of such LL-37/protein interactions are
currently under investigation in our laboratory.
The glucan and chitin layers of the C. albicans cell wall are
buried beneath a thin but dense mannan layer [11]. We found that
LL-37 interacts with mannan, chitin, and glucan (Fig. 5B).
Moreover, compared with mannan, chitin and glucan were less
able to rescue LL37-mediated cell aggregation and its ability to
inhibit cell adhesion (Fig. 5D and 5E). Although this result
supports previous findings that mannan is the most important C.
albicans adhering glycan [56] and that loss of phosphomannan
correlates with reduced levels of the AMP dermaseptin S3 bound
to the cells [57], it also raises the possibility that LL-37 interferes
with C. albicans cell-wall remodeling. It is thought that some
proteins with enzymatic activity on the C. albicans cell surface could
be bound by LL-37, leading to dysfunction of carbohydrate
metabolism [58], impairment of cell-wall construction, and
prevention of C. albicans/host adhesion. C. albicans cell-wall
remodeling occurs during infection and drug (e.g., caspofungin)
treatment, and consequently the inner glucan layer is exposed
during remodeling [59,60]. Characterization of the effects caused
by LL-37 on cell-wall remodeling will be investigated in future
studies.
Finally, AMP-mediated cellular aggregation has been reported.
The AMP L8 causes cellular aggregation of E. coli and Listeria
monocytogenes, two important food-borne pathogens [61]. In
addition, human neutrophil defensins induce aggregation of E.
coli and Staphylococcus aureus and may, in part, increase bacteria
uptake by neutrophils [62]. Similarly, human b-defensins bind
bacterial components and thereby enhance microbial ingestion by
dendritic cells [63]. We found that in addition to the association of
LL-37 and C. albicans and the reduction in cell adhesion to
polystyrene, floating cells aggregated—mediated by LL-37 bound
to the cells (Fig. 2 and 3). Although the biological function of cell
aggregation is not clear, we hypothesize that LL37-mediated
aggregation may help C. albicans escape further attack by LL-37 or
may allow phagocytes to easily recognize the pathogen.
In summary, our results revealed that LL-37 prevents C. albicans
adhesion to polystyrene and tissues, in part by interacting with cell-
wall carbohydrates. Our study highlights the potential use of LL-
37 as an effective therapeutic or preventive agent against C. albicans
infection. C. albicans polysaccharides could also be targeted by





RTES), biotinylated LL-37 (BA-LL37), biotinylated human b-
defensin-3 (BA-hBD3, QKYYCRVRGGRCAVLSCLPKEE-
QIGKCSTRGRKCCRRKK), and biotinylated histatin 5 (BA-
Hst 5, DSHAKRHHGYKRKFHEKHHSHRGY) were synthe-
sized by MDBio, Inc. (Taipei, Taiwan). HPLC and mass
spectrometry showed that the peptides were 96–98% pure. All
reagents were obtained from Sigma-Aldrich unless indicated
otherwise.
C. albicans strains, media, and growth conditions
The C. albicans SC5314 [64] cell was maintained at 280uC and
plated onto YPD agar (1% yeast extract, 2% Bacto-peptone, 2%
glucose and 1.5% agar) before each experiment. One colony was
added into YPD broth and incubated at 30uC overnight (,14 h).
This culture was then sub-cultured in YPD broth for ,2.5 h until
logarithmic-phase growth was reached. For LL-37 treatment, cells
were washed twice with phosphate-buffered saline (PBS), collected
by centrifugation, and suspended in Gibco RPMI-1640 medium
(Invitrogen, Carlsbad, CA) or in PBS for LL-37-binding
experiments. C. albicans cell-wall carbohydrates were removed
with GlycoPro
TM Enzymatic Deglycosylation kit reagents (Pro-
zyme, San Leandro, CA) according to the manufacturer’s
instructions.
Assays for LL-37 candidacidal activity
To assess LL-37 candidacidal activity, a spot assay and the
FUN-1 staining assay were used. After a 30-min incubation, LL-
37-treated cells were collected and their solutions were subjected
to 10-fold serial dilution. Cells (10 ml) were spotted onto YPD agar
plates. Cell viability was assessed after incubation at 30uC for 24 h.
FUN-1 staining was performed using LIVE/DEADH Yeast
Viability kit reagents (Molecular Probes, Eugene, OR) according
to the manufacturer’s instructions and (21). Briefly, after LL-37
treatment for 30 min, C. albicans cells were harvested by
centrifugation and suspended in 500 ml of 10 mM HEPES
containing 2% glucose and 5 mM FUN-1 for 30 min at 30uCi n
the dark. Samples were then examined using a FACSCalibur
analyzer (BD Bioscience, San Jose, CA) equipped with a diode
laser (excitation wavelength 488 nm). The intensities of the yellow-
green fluorescence emission from cells that had or had not been
treated with LL-37 were recorded after the light had passed
through an FL1 filter (515–545 nm). A total of 10,000 cells were
acquired per experiment. The mean fluorescence index of the
LL37-treated cells was compared with that of the control cells
(no LL-37 treatment). The relative number of dead cells is
reported as a percentage.
C. albicans adhesion to polystyrene
The adhesion of C. albicans was assayed using uncoated, flat-
bottom, 24-well plates (Orange Scientific, Braine-I’Alleud, Bel-
gium) or uncoated, 96-well plates (Nunc
TM, Rochester, NY) as
described [65,66]. For the XTT reduction assay, C. albicans cells
were harvested, washed, and suspended in RPMI-1640 medium at
a concentration of ,6610
7 cells/ml. Next, 250 ml of each cell
suspension was transferred into a well of a 24-well plate. Different
concentrations of LL-37, BA-LL37, BA-hBD3 or BA-Hst 5 were
independently added to the cell suspensions that were then
incubated at 37uC for 30 min with shaking (100 rpm). The
metabolic activities of the sessile cells were measured by detecting
the reductive adduct of XTT [67]. Briefly, cells were washed three
times with PBS to remove floating cells. Adherent cells were
incubated with 300 ml XTT (1 mg/ml) and 0.6 ml menadione
(1 mM) in PBS per well at 37uC for 20 min. Absorbance at 490 nm
was determined using a VICTOR3 Multilabel Plate Reader
(PerkinElmer). For the competition assays, LL-37 was premixed
with 400 mM of a monosaccharide or 1 mg/ml of a polysaccharide
in RPMI-1640 for 30 min at 4uC before incubating the LL-37/
polysaccharide mixture and the cells. All carbohydrate stock
solutions were prepared in PBS. C. albicans cell-wall mannan was
obtained from Takara Bio Inc. (Otsu, Japan). Mannan from S.
cerevisiae (M7054), glucan from S. cerevisiae (G5011), and chitin from
crab shells (C9752) were purchased from Sigma-Aldrich.
Cell ELISAs were performed using a similar procedure, except
that 100 mlo f5 610
7 cells/ml were used for each assay. The
adherent cells were fixed with 3% paraformaldehyde and labeled
with FITC-conjugated rabbit polyclonal antibody against C.
albicans (Biodesign International, Saco, ME). Fluorescence was
detected using a VICTOR3 Multilabel Plate Reader. The relative
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fluorescence for each treated cell sample)/(mean absorbance or
fluorescence for the control sample)]6100%. All assays were
performed in triplicate and repeated three or four times.
Microscopic visualization of floating C. albicans cells
After incubation with different LL-37 concentrations in the
wells of 24-well plates, the floating C. albicans cells were collected
and injected into m-Slides VI flat (Ibidi, Martinsried, Germany).
Samples were analyzed with a Zeiss light microscope.
Assays for LL-37 binding to floating C. albicans cells
C. albicans cells were suspended in PBS, mixed with BA-LL37 in
the wells of 24-well plates, and incubated at 4uC for 30 min.
Floating cells were collected by centrifugation, suspended in
reducing sample buffer, and denatured by heating at 100uC for
10 min. The samples were separated through a 15% Tricine SDS-
PAGE gel (prepared with a 40% acrylamide/Bis solution; MDBio,
Inc., Taipei, Taiwan), and transferred onto a polyvinylidene
difluoride (PVDF) membrane (Pall Corporation, Port Washington,
NY). BA-LL37 binding to C. albicans was detected using SA-HRP
according to the manufacturer’s instructions (Zymed Laboratories,
San Francisco, CA). The blots were processed using ECL kit
reagents (PerkinElmer Life Sciences).
Binding of antimicrobial peptides to C. albicans cells
AMPs bound to C. albicans were detected as described [48]. A
total of 6610
6 cells were mixed with different concentrations of
BA-LL37 or with 2.12 mM BA-LL37, BA-hBD3, or BA-Hst 5 in
750 ml PBS and then incubated at 4uC overnight. Cell-bound
peptide was assessed by flow cytometry with SA-DTAF detection
(3 mg/reaction; Jackson ImmunoResearch, West Grove, PA).
Reactions were quantitated using a FACSCalibur flow cytometer.
Fluorescence data for 10,000 cells were acquired per experiment.
The relative amount of an AMP bound to the cells (as a
percentage) was obtained by comparing the mean fluorescence
intensity emitted from the BA-hBD3- or BA-Hst 5-treated cells
with that of BA-LL37-treated cells. Additionally, the relative levels
of BA-LL37 and BA-Con A bound to cells that had or had not
been deglycosylated were determined.
Binding of LL-37 to polysaccharides
Polysaccharide binding assays were performed as described [68]
with modifications. Mannan-agarose (M9917; Sigma-Aldrich),
glucan, and chitin were each incubated with 10 mg BA-LL37 in
750 ml PBS with gentle rotation at 4uC overnight. The samples
were pelleted and washed twice with 1 ml PBS. The pellets were
suspended in reducing sample buffer and denatured by heating at
100uC for 10 min. The polysaccharide-bound BA-LL37 samples
were electrophoresed through a 15% Tricine SDS-PAGE gel,
transferred to a PVDF membrane, and detected using SA-HRP
and ECL kit reagents according to the manufacturer’s instructions.
Measurement of dissociation constants for LL-37/
mannan complexes
Dissociation constants (Kd) for the LL-37/mannan complexes
were measured using quartz crystal microbalance methodology
[69]. The amine surfaces of gold electrodes on a quartz chip were
purchased from ANT Technology Co., Ltd. (Taipei, Taiwan) and
were activated with 2.5% glutaraldehyde. Mannans from S.
cerevisiae and C. albicans (100 mg/ml each) were each cross-linked
with glutaraldehyde and then coated onto a chip. The binding
assay was performed using an Affinity Detection System (ANT
Technology). Before each experiment, the system was equilibrated
with PBS (pH 7.4) at the flow rate of 50 ml/min. For Kd
measurements, the LL-37 samples (0.1 to 1.6 mM for mannan
from C. albicans; 1 to 10 mM for mannan from S. cerevisiae) were
individually injected onto a chip surface that contained one of the
yeast cell-wall mannans. All the experiments were performed in
duplicate (for mannan from C. albicans) or triplicate (for mannan
from S. cerevisiae). The Kd values were calculated using Prism 5.0
(GraphPad Software Inc., La Jolla, CA).
Adhesion of C. albicans to oral epidermal cells
The oral epidermoid carcinoma cell line (OECM-1) was kindly
provided by Dr. Tzong-Ming Shieh (China Medical University,
Taiwan). The cells were grown in RPMI-1640 medium containing
10% (v/v) heat-inactivated fetal bovine serum (BSR BIO), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin
(Biosera East Sussex, UK) at 37uC under a 5% CO2 atmosphere.
To determine how well C. albicans adhered to the oral epithelial
cells, a protocol similar to that of the cell ELISA experiment was
used, except that 5610
4 OECM-1 cells were first grown to 95%
confluency in wells of a 96-well plate. Thirty minutes prior to the
start of the experiment, 100-ml samples of the cells (1610
7 cells/
ml) were prepared in RPMI-1640 that contained different
concentrations of LL-37 at 4uC. Then, the treated C. albicans cells
were incubated with the OECM-1 cells at 4uC for another 30 min.
The percentage of adhered cells was calculated as follows: [(mean
fluorescence for LL-37-treated cells)/(mean fluorescence for
control cells)]6100%. All assays were performed in quadruplicate
and repeated four times.
Mouse model for C. albicans adhesion
All animal studies were approved by the Institutional Animal
Care and Use Committees of the National Tsing Hua University
(approval number 09730) and the Animal Technology Institute
Taiwan (approval number 97010). Adhesion of C. albicans to
mouse bladder epithelia was assayed as described [36] with
modifications. Briefly, 20- to 24-week-old female BALB/c mice
(BioLasco Taiwan Co., Ltd.) were deprived of water overnight.
Mice under anesthesia were each transurethrally catheterized with
100 ml of a LL-37 (5 mg/ml) and C. albicans mixture (2610
7 cells)
using soft, sterile polyethylene tubing (PE 10, outside diameter
0.61 mm, inside diameter 0.28 mm, Clay Adams, Becton Dick-
inson) that had been lubricated. After 1 h of catheterization, the
mice were sacrificed and their urinary bladders were removed.
The bladders were washed four times with 1 ml PBS and
homogenized using a tissue grinder. The number of colony-
forming units of C. albicans cells that adhered to each bladder was
determined by plating serially diluted samples (in PBS) onto YPD
agar that contained 50 mg/ml ampicillin and incubating the plates
at 30uC overnight. Relative cell adhesion was calculated as follows:
[(number of colony-forming units of each bladder/(average
number of colony-forming units of all bladders]6100%. Differ-
ences in the adhesion for C. albicans–injected mouse bladders were
determined using GraphPad Prism 5.0 software.
Statistical analysis
Data were assessed for statistical significance by the two-tailed
Student’s t-test.
Supporting Information
Figure S1 Adhesion of LL-37-treated cells to centrifuga-
tion tubes. C. albicans was treated with 5 mg/ml LL-37 for
30 min, pelleted by centrifugation, and then the number of cells
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visual inspection. Upper panels: 50-ml centrifuge tubes; lower
panels: 1.5-ml microcentrifuge tubes; left panels: cells after
centrifugation; right panels: cells after removal of the supernatant;
left tube in each panel: control cells (no LL-37 treatment); right
tube in each panel: cells treated with 5 mg/ml LL-37.
(TIF)
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